Bowen Hanes & Co’s United Therapeutics UTHR Stock Holding History

Bowen Hanes & Co’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$50.4M	Hold	85,000	–	–	1.23%	42
2026 Q1	$50.4M	Buy	+85,000	New	+$42.3M	1.23%	42

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Bowen Hanes & Co's UTHR Position: Q2 2026 in Review

Bowen Hanes & Co held its United Therapeutics (UTHR) position steady in Q2 2026 at 85,000 shares worth $50.4M. The position accounts for 1.23% of the portfolio, ranked #42.

Bowen Hanes & Co first reported a position in UTHR in Q1 2026 and has held it in 2 quarters since. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Bowen Hanes & Co held 85,000 shares of United Therapeutics worth $50.4M as of Q2 2026.
Bowen Hanes & Co left its United Therapeutics share count unchanged in Q2 2026.
United Therapeutics made up 1.23% of Bowen Hanes & Co's portfolio in Q2 2026, its #42 holding.
Bowen Hanes & Co first reported a position in United Therapeutics in Q1 2026 and has held it in 2 quarters since.
878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Bowen Hanes & Co's 13F filing for Q2 2026, filed 13 Aug 2026.